12 June, 2020 in Allgemein Pantherna Therapeutics GmbH signs an agreement for technology evaluation with Astellas Innovation Management LLC to evaluate Pantherna’s lipid nanoparticle transport system and mRNA molecules.
02 April, 2020 in Allgemein Successful follow-up financing for Pantherna Therapeutics’ development programs to fight Acute Respiratory Distress Syndrome
26 March, 2020 in Allgemein Pantherna Therapeutics GmbH and PROVIREX Genome Editing Therapies GmbH are developing lipid-based delivery systems for mRNA-directed genome editing of lymphocytes for the treatment of HIV and other life-threatening persistent viral diseases
20 February, 2020 in Allgemein Pantherna Therapeutics presented at the RNA Therapeutics Conference in London, UK
02 October, 2019 in Allgemein Pantherna Therapeutics to present at the Creative Transformative Medicine Europe User Group Meeting
03 July, 2019 in Allgemein “First-in-Class“ mRNA-therapeutics for vascular diseases: Pantherna Therapeutics receives 7-digit investment
17 October, 2018 in Allgemein Pantherna Therapeutics participated as a finalist at BioRiver Boost! 2018 in Wuppertal
01 August, 2018 in Allgemein Pantherna Therapeutics filed its first patent application “Recombinant nucleic acid construct”
